These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 505407)

  • 1. In vitro effect of p-chlormercuribenzoate upon dilute blood clot lysis time in hyperlipemia.
    Cucuianu MP; Stef C; Zdrenghea D; Popescu O
    Thromb Haemost; 1979 Oct; 42(3):929-44. PubMed ID: 505407
    [No Abstract]   [Full Text] [Related]  

  • 2. Alpha 2-antiplasmin, plasminogen activator inhibitor (PAI) and dilute blood clot lysis time in selected disease states.
    Cucuianu M; Knauer O; Roman S
    Thromb Haemost; 1991 Nov; 66(5):586-91. PubMed ID: 1725069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Behaviour of platelet adhesiveness and of dilute clot blood lysis time in hyperlipoproteinemic subjects.
    Zdrenghea D; Stef C; Cucuianu M; Vlaicu R
    Med Interne; 1979; 17(3):273-7. PubMed ID: 504931
    [No Abstract]   [Full Text] [Related]  

  • 4. [Primary hyperlipoproteinemia in its clinical and laboratory aspects. IV. Blood coagulation and fibrinolysis indicators].
    Borodin M; Jurek D; Gregorczyk J; Pieczul-Mróz J; Cwajda H
    Przegl Lek; 1983; 40(10):727-32. PubMed ID: 6665208
    [No Abstract]   [Full Text] [Related]  

  • 5. [Rapid changes in blood lipid parameters induced by glucuronyl glucosamine glycan sulfate in obese diabetic and hyperlipidemia patients].
    Ferlito S; La Spina E; Fichera C; Cultrera E; Patanè M; Ciulla P
    Arch Sci Med (Torino); 1982; 139(4):441-8. PubMed ID: 7168636
    [No Abstract]   [Full Text] [Related]  

  • 6. [Plafibride treatment of hyperlipidemias type II and IV].
    Soler J; Vinzia C; Gómez JM; Morató J
    Med Clin (Barc); 1984 May; 82(19):840-2. PubMed ID: 6738212
    [No Abstract]   [Full Text] [Related]  

  • 7. [Behavior of serum lipids, blood coagulation factors, platelet aggregation, complement and serum immunoglobulins in a group of arteriosclerotic, hyperlipemic subjects treated with 3GS].
    D'Eredità F; Avellone G; Novo S; Davì G; Abruzzese G; Di Liberti M; Pinto A; Riolo F
    Clin Ter; 1981 Feb; 96(3):303-24. PubMed ID: 7307448
    [No Abstract]   [Full Text] [Related]  

  • 8. [Hyperlipoproteinemia, HDL-cholesterol and arteriosclerosis indices].
    Herrmann W; Reuter W
    Z Gesamte Inn Med; 1982 Dec; 37(24):830-3. PubMed ID: 6963524
    [No Abstract]   [Full Text] [Related]  

  • 9. [Subfractions of HDL cholesterol. Occurrence in hyperlipoproteinemia type IIa and IV].
    Mertz DP; Thuilot G; Bürvenich K
    Fortschr Med; 1986 Jul; 104(26):508-10. PubMed ID: 3744260
    [No Abstract]   [Full Text] [Related]  

  • 10. Fibrinolysis in diabetes mellitus. Role of overweight and hypertriglyceridemia.
    Cucuianu M; Fekete T; Marcusiu C; Mösler R; Duţu A
    Med Interne; 1984; 22(3):171-7. PubMed ID: 6494764
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Dyslipoproteinemia and blood levels of various microelements in patients with hypertension living in the areas of different altitudes and climate].
    Bobokhodzhaev IIa
    Klin Med (Mosk); 1987 Aug; 65(8):38-42. PubMed ID: 2960851
    [No Abstract]   [Full Text] [Related]  

  • 12. [Evaluation of the pseudocholinesterase activity in hyperlipoproteinemia type II and type IV].
    Averna MR; Montalto G; Rini GB; Di Fede G; Labisi M; Marino G; Notarbartolo A
    Boll Soc Ital Biol Sper; 1983 Apr; 59(4):520-4. PubMed ID: 6882547
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Hemostatic parameters in patients with type IIA and IV hyperlipoproteinemia].
    Ferlito S; Torrisi A; Marangio S; Palermo A; Condorelli M; Mazzone D
    Minerva Cardioangiol; 1992 Jun; 40(6):211-7. PubMed ID: 1407615
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Cholesterol and triglyceride plasma levels in patients with primary hyperlipoproteinemia. Decline after short-term i.v. glucagon administration].
    Andĕl M; Brodan V; Kucerová L; Grafnetter D; Kuhn E; Veselková A
    Cas Lek Cesk; 1980 May; 119(22):616-21. PubMed ID: 7427980
    [No Abstract]   [Full Text] [Related]  

  • 15. [Gemfibrozil in the treatment of hyperlipoproteinemias].
    Monova D; Petrova V; Belovezhdov N
    Vutr Boles; 1991; 30(2):56-8. PubMed ID: 1891900
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Musculoskeletal symptoms in patients with primary hyperlipoproteinemia. A prelimary study].
    Brekke SE; Kogstad OA
    Tidsskr Nor Laegeforen; 1979 Oct; 99(29):1444-6. PubMed ID: 516016
    [No Abstract]   [Full Text] [Related]  

  • 17. [Effect of bezafibrate therapy on serum and lipoprotein lipids].
    Romics L; Németh Csóka M; Szám I; Pados G; Karádi I; Köszegi G; Kusztos R
    Orv Hetil; 1986 Oct; 127(40):2425-8, 2431. PubMed ID: 3537905
    [No Abstract]   [Full Text] [Related]  

  • 18. Serum lipoprotein pattern after SAMe-treatment.
    Rini GB; Di Fede G; Rotolo G; Rizzo G; Mascellino MR; Affronti M; Delle Vedove G
    Boll Soc Ital Biol Sper; 1987 Oct; 63(10):919-22. PubMed ID: 3447603
    [No Abstract]   [Full Text] [Related]  

  • 19. [Platelet aggregation in whole blood and prostacyclin in hyperlipemia types II and IV].
    Craveri A; Lanfredini M; Citella C; Barbesti S; Tempesta A; Gallo E
    Minerva Med; 1988 May; 79(5):349-54. PubMed ID: 3374826
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [HDL, HDL2 and HDL3 cholesterol in various types of hyperlipoproteinemia in relation to clinical signs of arteriosclerosis].
    Sznajderman M; Zawadzki Z
    Kardiol Pol; 1986; 29(3):194-203. PubMed ID: 3773408
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.